Synmosa Biopharma Corporation (TPEX:4114)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.90
-0.05 (-0.16%)
Apr 28, 2026, 1:30 PM CST
7.38%
Market Cap 15.54B
Revenue (ttm) 6.19B
Net Income (ttm) 821.85M
Shares Out 502.77M
EPS (ttm) 1.66
PE Ratio 18.61
Forward PE n/a
Dividend 0.55 (1.76%)
Ex-Dividend Date Jul 11, 2025
Volume 563,297
Average Volume 834,311
Open 30.95
Previous Close 30.95
Day's Range 30.70 - 31.00
52-Week Range 28.82 - 39.80
Beta 0.02
RSI 40.44
Earnings Date Aug 28, 2026

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale r... [Read more]

Sector Healthcare
Founded 1959
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4114
Full Company Profile

Financial Performance

In 2025, Synmosa Biopharma's revenue was 6.19 billion, an increase of 11.53% compared to the previous year's 5.55 billion. Earnings were 821.85 million, an increase of 20.03%.

Financial Statements

News

There is no news available yet.